Back to Journals » Drug Design, Development and Therapy » Volume 4

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections

Authors Zoller E, Valente C, Baker K, Klepser M

Published 4 November 2010 Volume 2010:4 Pages 299—311

DOI https://doi.org/10.2147/DDDT.S7773

Review by Single-blind

Peer reviewer comments 3


Emily Zoller, Connie Valente, Kyle Baker, Michael E Klepser
Ferris State University College of Pharmacy, Kalamazoo, Michigan, USA

Abstract: Posaconazole is an extended-spectrum azole antifungal that exhibits activity against a broad range of fungal pathogens, including yeasts and moulds. Clinical data have demonstrated the clinical utility of posaconazole against many therapy-refractory pathogens, including Aspergillus spp, Fusarium spp, and Zygomycetes. These data have provided clinicians with hope in these difficult situations. Some of the limitations that have emerged with the use of posaconazole are the lack of an intravenous formulation and erratic drug absorption. This fact is further complicated by the existence of saturable posaconazole absorption. Despite these drawbacks, posaconazole appears poised to become a prominent therapeutic modality for the prophylaxis and management of various fungal infections among high-risk patients.

Keywords: posaconazole, pharmacokinetics, fungal infections

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]